Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
MAINZ, Germany, Feb. 22, 2017 -- BioNTech AG, a fully integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that Sean Marett, COO of BioNTech, will be presenting at Cowen and Company’s 37th Annual Health Care Conference that is being held in Boston, MA from March 6 - 8, 2017. The presentation is scheduled for Tuesday, March 7 at 10:00 AM Eastern Standard Time.
Mr. Marett will provide an overview of the Company´s strategy and its most recent substantial progress, including an update of its clinical pipeline, an overview of its strategic collaborations, a summary of its two most recent Nature publications related to its individualized mRNA cancer immunotherapeutics and the establishment of a GMP conform mRNA production facility at the Company´s headquarters in Germany.
About BioNTech AG
BioNTech is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The company combines all building blocks for individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators. BioNTech´s approach is validated by five top-tier corporate partnerships with Genentech, Genmab, Eli Lilly, Sanofi and Bayer Animal Health. Founded in 2008, BioNTech’s shareholders include the MIG Fonds, Salvia and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder. More information about BioNTech is available at www.biontech.com.
For meeting requests or further information, please contact: BioNTech AG Regina Jehle Tel: +49 6131 9084 1273 Email: [email protected] U.S. Media and Investor Inquiries: ICR, Inc. James Heins/Stephanie Carrington Tel. 203-682-8251 Tel. 646-277-1282 [email protected] [email protected] International Media & Investor Inquiries akampion Dr. Ludger Wess / Ines-Regina Buth Tel. +49 40 88 16 59 64 Tel. +49 30 23 63 27 68 [email protected]
